Clinical Trial Detail

NCT ID NCT03207867
Title A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals

pancreatic cancer

renal cell carcinoma

triple-receptor negative breast cancer

head and neck cancer

transitional cell carcinoma

diffuse large B-cell lymphoma

colon cancer



PBF-509 + Spartalizumab

Age Groups: adult senior

No variant requirements are available.